secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001628280-23-002862
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter reports Q4 sales $3.9B, full-year GAAP loss of $4.83 per share; spinoff update
--------------------------------------------------------------------------------

- Q4 revenue $3.9B (+11% reported, +17% constant currency); GAAP EPS $0.36, adjusted EPS $0.88.
- Full-year sales $15.1B (+18% reported); GAAP diluted EPS loss ($4.83); adjusted EPS $3.50.
- Company reiterates plans to spin off Renal Care and Acute Therapies into a new kidney care company.
- CEO cites ongoing macroeconomic and supply chain headwinds weighing on performance.
- Guidance for 2023 provided in full press release; no specific numbers in excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023002862/0001628280-23-002862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023002862/bax-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer